Iantrek completed $23 million Series B Round funding
Sector:
MedTech
08/30/2022
White Plains, NY USA
Iantrek
completed $23 million Series B Round funding. Investors include
Sectoral Asset Management (lead), Visionary Ventures (lead).
“There remains a significant unmet clinical need to provide safe and effective micro-interventional tools for aqueous outflow management,” said Dr. Ianchulev, who is also Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai and Director of Ophthalmic Innovation and Technology at the New York Eye and Ear Infirmary of Mount Sinai. “We are grateful to have a world-class syndicate of investors supporting our efforts to advance these new technologies. With two commercial ready MIGS platforms, Iantrek is uniquely positioned to transform the horizon of micro-interventional ophthalmic surgery.”
About
Founded by ophthalmic innovator Sean Ianchulev, MD, MPH, Iantrek is a venture-funded medical technology company pioneering bio-interventional and micro-interventional products for ophthalmic surgery. The company’s portfolio includes AlloSert™ Uveo, AlloFlo™ Uveo, CanaloFlo™, and C.Rex™— bio-interventional and micro-interventional solutions for the management of glaucoma.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
